Management of residual mass in advanced seminoma: Results and recommendations from the Memorial Sloan-Kettering Cancer Center

Journal of Clinical Oncology

Volumn 14, Issue 2, 1996, Pages 454-460

  Puc, H S ^a   Heelan, R ^a   Mazumdar, M ^a   Herr, H ^a   Scheinfeld, J ^a   Vlamis, V ^a   Bajorin, D F ^a   Bosl, G J ^a   Mencel, P ^a   Motzer, R J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SIZE; CANCER SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; SCHOOL CHILD; SEMINOMA; TUMOR VOLUME;

EID: 9044243757     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.2.454     Document Type: Article

References (23)

1. Mencel PJ, Motzer RJ, Mazumdar M, et al: Advanced seminoma: Treatment results, survival, and prognostic factors in 142 patients. J Clin Oncol 12:120-126, 1994
2. Einhorn LH, Williams SD, Loehrer PJ, et al: Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: A Southeastern Cancer Study Group protocol. J Clin Oncol 7:387-391, 1989
3. Stanton GF, Bosl GJ, Whitmore WFJ, et al: VAB-6 as initial treatment of patients with advanced seminoma. J Clin Oncol 3:336-339, 1985
4. Friedman EL, Garnick MB, Stomper PC, et al: Therapeutic guidelines and results in advanced seminoma. J Clin Oncol 3:1325-1332, 1985
5. Motzer R, Bosl G, Heelan R, et al: Residual mass: An indication for further therapy in patients with advanced seminoma following systemic chemotherapy. J Clin Oncol 5:1064-1070, 1987
6. SAS/STAT User's Guide (ed 4). Cary, NC, SAS Institute, 1990
7. Miller R, Siegmund D: Maximally selected chi square statistics. Biometrics 38:1011-1016, 1982
8. Altman DG, Lausen B, Sauerbrei W, et al: Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86:829-835, 1994
9. Herr HW, Bosl G: Residual mass after chemotherapy for seminoma: Changing concepts of management. J Urol 137:1234-1235, 1987
10. Schultz SM, Einhorn LH, Conces DJJ, et al: Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience. J Clin Oncol 7:1497-1503, 1989
11. Fossa SD, Kullmann G, Lien HH, et al: Chemotherapy of advanced seminoma: Clinical significance of radiological findings before and after treatment. Br J Urol 64:530-534, 1989
12. Peckham MJ, Horwich A, Hendry WF: Advanced seminoma: Treatment with cis-platinum-based combination chemotherapy or carboplatin (JM8). Br J Cancer 52:7-13, 1985
13. Nichols CR, Breeden ES, Loehrer PJ: Secondary leukemia associated with a conventional dose of etoposide: Review of serial germ cell tumor protocols. J Natl Cancer Inst 85:36-40, 1993
14. Horwich A, Dearnaley DP, Duchesne GM, et al: Simple nontoxic treatment of advanced metastatic seminoma with carboplatin. J Clin Oncol 7:1150-1156, 1989
15. Srougi M, Simon SD, Meneyes DG: Vinblastine, actinomycin-D, bleomycin, cyclophosphamide, and cisplatin for advanced germ cell testis tumors: Brazilian experience. J Urol 134:65-69, 1985
16. Bosl GJ, Geller NL, Bajorin D, et al: A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol 6:1231-1238, 1988
17. Bajorin DF, Sarosdy MF, Pfister DG, et al: Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: A multiinstitutional study. J Clin Oncol 11:598-606, 1993
18. Fossa SD, Borge L, Gass N, et al: The treatment of advanced metastatic seminoma: Experience in 55 cases. J Clin Oncol 5:1071-1077, 1987
19. Ellison MF, Mostofi FK, Flanigan RC: Treatment of the residual retroperitoneal mass after chemotherapy for advanced seminoma. J Urol 140:618-620, 1988
20. Bokemeyer C, Schmoll HJ: Treatment of testicular cancer and the development of secondary malignancies. J Clin Oncol 13:283-292, 1995
21. Weissbach L, Hartlapp JH: Adjuvant chemotherapy of metastatic stage II nonseminomatous testis tumor. J Urol 146:1295-1298, 1991
22. Loehrer PJ, Birch R, Williams SD, et al: Chemotherapy of metastatic seminoma: The Southeastern Cancer Study Group experience. J Clin Oncol 5:1212-1220, 1987
23. Bosl GJ, Geller NL, Chan EY: Stage migration and the increasing proportion of complete responders in patients with advanced germ cell tumors. Cancer Res 48:3524-3527, 1988